Early Access — free while we kick the tires
EdgarHawk

van Houte Hans

Chief Financial Officer

Officer
1 filing analyzed · 1 company · Latest 2024-08-26

Companies

Company Buys Sells Direction
Nurix Therapeutics, Inc. NRIX 0 1 Net selling

Activity

August 2024
high
Sell
20,000 shares
$504,370
Significance 6/10

CFO van Houte Hans sold 20,000 NRIX shares at $25.22, reducing holdings by 39.2%, as stock rebounds 65.3% in 90 days.

CFO van Houte Hans sold 20,000 shares (39.2% of pre-transaction holdings) at $25.22 on 2024-08-26, leaving him with 31,002 shares. The transaction occurs against a backdrop of significant positive price momentum: the stock has risen 65.3% over the past 90 days and currently trades at $25.69, near its 52-week high of $25.69. However, the company's fundamentals present a mixed picture. While revenue growth of 99.3% year-over-year demonstrates strong business expansion with quarterly revenue of $12.1M, Nurix remains unprofitable with a net loss of $44.5M over its most recent full fiscal year. The sale represents a material reduction in executive stake during a period of stock appreciation, though it occurred at a price point near current market levels rather than at depressed valuations.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access